Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. - Wikidata - awgldk - TriplyDB

Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.

Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.

http://www.wikidata.org/entity/Q34782224

about

Novel strategies for the treatment of asthma Biological Treatments in Atopic Dermatitis Personalized Medicine in Allergy Therapeutic interventions in severe asthma Target-oriented therapy: Emerging drugs for atopic dermatitis.Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange.IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.Emerging biologics for the treatment of chronic rhinosinusitis.The future of biologics: applications for food allergy.Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study.Implementation of highly sophisticated flow cytometry assays in multicenter clinical studies: considerations and guidance.Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies.Asthma treatments: new and emerging therapies.Pharmacological Management of Chronic Rhinosinusitis: Current and Evolving Treatments.IgE Depletion in Severe Asthma: What We Have and What Could Be Added in the Near Future.Looking forward to new targeted treatments for chronic spontaneous urticaria.Targeted therapeutics for severe refractory asthma: monoclonal antibodies.From IgE to Omalizumab.CTLA4Fcε, a novel soluble fusion protein that binds B7 molecules and the IgE receptors, and reduces human in vitro soluble CD23 production and lymphocyte proliferation.Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody.The path to personalized medicine in asthma.Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update.Update on Potential Therapies for IgE-Mediated Food Allergy.Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies.Atopic dermatitis phenotypes and the need for personalized medicine.The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis.Endotype-driven treatment in chronic upper airway diseases.Developments in the field of allergy in 2014 through the eyes of Clinical and Experimental Allergy.Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus.An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases.Novel Therapeutic Approaches to Atopic Dermatitis.Biologic agents for severe asthma patients: clinical perspectives and implications.New approaches for identifying and testing potential new anti-asthma agents.Combining anti-IgE with oral immunotherapy.Urticaria and Angioedema: an Update on Classification and Pathogenesis.Anti-IgE and Biologic Approaches for the Treatment of Asthma.A next-generation anti-IgE monoclonal?Monoclonal Antibodies for the Management of Severe Asthma.

P2860

Q26748993-D0D7D91E-8CC6-480D-B19D-7055054EB610 Q26799579-7A47E02E-0FE8-4DC7-8AF8-86F159AF570F Q28073074-7121EA46-F22F-4F6F-9DB1-374AE0C82523 Q28079238-8084BA73-0A32-4C36-8393-7E1F914DE1FD Q34510687-98DD3F4D-FC41-4268-9FFE-C46E26C521BC Q36919753-646A5DCF-DBE8-4393-8F5A-CEA918EE0418 Q37554168-B2217A93-0DE2-4008-9A2F-90C4C3DA4373 Q38344266-C4491728-01E9-496A-ACE9-4A29EA501E98 Q38348057-D42BE0C4-68DE-4454-A897-CE54464C321F Q38396322-57970DE4-6F8E-4DB3-8A3E-5B77FD4A189C Q38516622-E67D373C-2EF3-4AF7-A586-E30957E1E369 Q38528048-FF7C6420-26B0-4471-A7F0-25A57B12E96E Q38579923-22EAD218-1539-4A5A-AC76-5CA3BD69EBBB Q38602604-D5F02C60-F0B9-486B-868A-B6D9C37C4448 Q38750724-5F405F9A-81E5-4EE5-9FD3-0E56DFE16B26 Q38771632-03F73D1F-F3D9-4F82-8611-7855F8CC9C72 Q38790815-A28942FA-516F-4A32-8111-E9C5173DA511 Q38793428-3803DFA6-DAD7-490E-9590-EEB503D4D5A1 Q38800276-78801D23-6DE9-4D32-AA0E-12FDFB6A198A Q38811111-7F257D49-6D65-4B39-A3E9-632D7A01C7BA Q38843261-B6AD3C0A-8674-45C0-8763-7641AAD684F6 Q38883893-96349D56-A810-45FC-A75E-1CD95ED85C1D Q38970557-805C8DF9-75C3-4FF0-9C6A-052D073220D4 Q39012896-6C43526A-777F-4D3F-8B92-1AF81A433B3F Q39108259-D2606B50-36A0-4A89-A302-48E43B1CB4B4 Q39352185-9A43AACD-0D4A-440B-B69A-DD12145B7266 Q39402846-10F0B767-5995-4AEC-9EF1-83337D19E31A Q39434071-B9632706-A5F9-489E-8032-861C4AF8785D Q40940984-741221F2-ECC3-41CC-B66A-B8FC52F71A9F Q41633977-62E5B631-0C31-48EE-B8B7-F338522EE1BD Q47144191-1E9B9A4A-8043-4F63-9F10-2AA4FB554664 Q47146658-AD6253C7-2F08-4124-9965-CA799242ACBC Q47569916-BBEC4BE2-7CFD-4692-B6C6-8FE5E5FDD9A9 Q47576873-6E90203A-778D-4DCD-89C5-6C1DB07BEE01 Q47873103-741620A0-0882-4CB2-B0DD-1AA28E5A567F Q48282763-86DE1F82-BEB5-49DF-B4D7-DDDA64C91284 Q48339085-4E6D8DA7-A268-4CEF-B395-3761283AD3CC Q50120034-006F7992-D828-4C26-80B6-66C2F3A17F56 Q51431195-5C533B6F-CCDF-4735-A98A-FE5203CE9C9D Q51687473-B39C56FE-1D16-46DB-AE76-FDD19194C17F

P2860

Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.

http://www.wikidata.org/entity/Q34782224

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Pharmacokinetics, pharmacodyna ...... antibody, in atopic subjects.

@ast

Pharmacokinetics, pharmacodyna ...... antibody, in atopic subjects.

@en

Pharmacokinetics, pharmacodyna ...... antibody, in atopic subjects.

@nl

type

label

Pharmacokinetics, pharmacodyna ...... antibody, in atopic subjects.

@ast

Pharmacokinetics, pharmacodyna ...... antibody, in atopic subjects.

@en

Pharmacokinetics, pharmacodyna ...... antibody, in atopic subjects.

@nl

prefLabel

Pharmacokinetics, pharmacodyna ...... antibody, in atopic subjects.

@ast

Pharmacokinetics, pharmacodyna ...... antibody, in atopic subjects.

@en

Pharmacokinetics, pharmacodyna ...... antibody, in atopic subjects.

@nl

P1433

Q34782224-94A2278B-B4B5-4F62-BDC9-2464DBC35932

P1476

Q34782224-89403EA4-610F-4A24-B355-F4F94FA7CFF6

P2093

Q34782224-09443363-5829-4BF9-8C7A-1BEFF3B47AD2

Q34782224-13CEC3AB-6B87-4843-AABA-4F63A4EF8C8C

Q34782224-3AACD7CB-C540-4ACF-BC70-C555A5A70A19

Q34782224-53E95599-B1E0-4FF0-9E44-9FB0C1383EA8

Q34782224-6ACAE620-9D26-4055-9605-C6D3AE67472C

Q34782224-6B7856E1-8AD7-4809-82D4-1E3A7407EBFC

Q34782224-D1B8057A-2612-40E2-B317-2A3699C7F3E9

Q34782224-F33BFE7E-5651-4B6E-867B-2BFDAE383506

P2860

Q34782224-05C9050F-2793-49E3-99C1-7370B4DD9802

Q34782224-1AC7AE16-9BC9-4526-8029-00DBB5B8D953

Q34782224-38D6E142-D030-44E4-8F04-6B20BE43305D

Q34782224-3A3C8BEE-0183-408E-9BF3-C870131DC3C4

Q34782224-5B021D78-3CE2-4C79-9037-49CDFDB11077

Q34782224-71CD5F19-A6C0-4C16-B7A5-896DA37C4A5E

Q34782224-782AE307-AA39-4161-A0C5-01CA409CF918

Q34782224-8D23BE45-1C8D-484D-8858-A556EB659A5F

Q34782224-96AF6256-928B-46C3-BA03-DA26C4791ADB

Q34782224-9F002337-9D9F-4988-915B-88874CF9E52D

P304

Q34782224-5C142AC1-CB95-402E-A11B-120693AFE400

P31

Q34782224-A5836C3A-C443-43E3-8ED4-2671C2F3B3FE

P356

Q34782224-E7F116BC-CF0B-4997-B809-30DD776D9E04

P433

Q34782224-2184AFD6-FA6F-4D0C-A038-2A79DB080B04

P478

Q34782224-65F477F6-CAA8-46C3-87BB-4C88136CC9F3

P50

Q34782224-4670B1E6-B221-4735-8129-7367965DEFC0

P577

Q34782224-17484E3D-D64B-4434-BE1D-59A3D006471C

P5875

Q34782224-D295D2F1-3788-4742-968C-4B0E98592D99

P698

Q34782224-7E838E78-5BB5-40A0-B7A6-0EC40FFB46B5

P921

Q34782224-4FB605B0-1A51-4716-B2F0-5F5C777DCD51

P932

Q34782224-ACA748DB-21F8-4DAB-B455-C174F75D0A08

P356

P1433

Clinical & Experimental Allergy

P1476

Pharmacokinetics, pharmacodyna ...... antibody, in atopic subjects.

@en

P2093

A Groenewegen

http://www.w3.org/2001/XMLSchema#string

A Skerjanec

http://www.w3.org/2001/XMLSchema#string

C E Owen

http://www.w3.org/2001/XMLSchema#string

D Floch

http://www.w3.org/2001/XMLSchema#string

I Bottoli

http://www.w3.org/2001/XMLSchema#string

I Jones

http://www.w3.org/2001/XMLSchema#string

J P Arm

http://www.w3.org/2001/XMLSchema#string

S Maahs

http://www.w3.org/2001/XMLSchema#string

P2860

Humanization of an antibody directed against IgE

Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.

Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge.

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function.

Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody.

Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.

Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma.

On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.

The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.

P304

1371-1385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CEA.12400

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265471197

http://www.w3.org/2001/XMLSchema#string

P698

25200415

http://www.w3.org/2001/XMLSchema#string

P921

P932

4278557

http://www.w3.org/2001/XMLSchema#string